Biologicals Secretariat:
Dr. Ryoko Krause
Director, Biologicals and Vaccines, IFPMA
e-mail: r.krause@ifpma.org
Tel: +41 22 338 32 00
 |
2008 04 02 |
IFPMA proposal for Naming of Monoclonal Antibody Drug Substances presented at the 46th WHO INN Consultation for Pharmaceutical Substances |
 |
2008 03 21 |
IFPMA Proposal to the WHO INN Expert Group: Principles for Naming of New Monoclonal Antibodies |
 |
2007 11 20 |
IFPMA Points to Consider in the drafting of WHO Guidelines for Biosimilar Medicinal Products |
 |
2007 10 02 |
Geneva Bio Forum: The Complexity of Biopharmaceuticals: Opportunities & Challenges of Biotech Medicines - Speakers' Biography |
 |
2007 10 02 |
What makes Biological Products unique? presented by Prof. dr. H. Schellekens, Utrecht University, NL at the Geneva Bio Forum |
 |
2007 10 02 |
Biotechnology Medicinal Products: Opportunities and Challenges presented by Dr. Kenneth B. Seamon, Institute of Biotechnology, University of Cambridge at the Geneva Bio Forum |
 |
2007 04 20 |
Regulatory evaluation of therapeutic biological medicines presented by Dr Jacques Mascaro Head, European Regulatory Affairs, F. Hoffmann-La Roche Ltd, CH, on behalf of IFPMA for the IFPMA presentation at the WHO Biotherapeutics meeting |
 |
2007 04 19 |
Regulatory evaluation of therapeutic biological medicines - erythropoietin and other examples presented by Andrew Fox, Director, Regulatory Affairs, Amgen, on behalf of IFPMA for the IFPMA presentation at the WHO Biotherapeutics meeting |
 |
2006 08 -- |
IFPMA Position on Follow-on Biological/Biotechnological Products |